Latest Conference News

IMDC Model Predicts OS After Second-line Targeted Therapy for mRCC

IMDC Model Predicts OS After Second-line Targeted Therapy for mRCC

The International Metastatic Renal Cell Carcinoma Database Consortium model is predictive of patient survival after targeted therapy for mRCC.

Inherited MET Oncogene Variant Prognostic for Survival, Time to Recurrence in Clear Cell RCC

Inherited MET Oncogene Variant Prognostic for Survival, Time to Recurrence in Clear Cell RCC

Patients with clear cell RCC and the inherited exonic MET rs11762213 had a worse clinical outcome.

Ipilimumab + RT Increases Median OS in Certain Patients with mCRPC

Ipilimumab + RT Increases Median OS in Certain Patients with mCRPC

Ipilimumab plus RT vs. RT alone increased median OS in patients with chemotherapy-naïve mCRPC and specific prognostic features.

Trimodal Therapy Effective in Invasive Bladder Urothelial Carcinoma Not Suitable for Cystectomy

Trimodal Therapy Effective in Invasive Bladder Urothelial Carcinoma Not Suitable for Cystectomy

Trimodal therapy is "appropriate" after transurethral surgery in muscle-invasive bladder urothelial carcinoma not suitable for cystectomy.

Radium-223: Long-term Follow-up Shows 'No Major Safety Issues'

Radium-223: Long-term Follow-up Shows 'No Major Safety Issues'

Radium-223 dichloride remains an "effective and well-tolerated" treatment for men with CRPC and bone metastases.

Novel Kinase Inhibitor Shows Efficacy in Patients with Advanced HCC Tumors Overexpressing AFP

Novel Kinase Inhibitor Shows Efficacy in Patients with Advanced HCC Tumors Overexpressing AFP

LY2157299 monohydrate showed promising efficacy results in patients with advanced HCC tumors overexpressing AFP.

CTCs Have High Specificity for Diagnosis of Pancreatic Ductal Adenocarcinoma

CTCs Have High Specificity for Diagnosis of Pancreatic Ductal Adenocarcinoma

Circulating tumor cells are a useful adjunct in the diagnosis of pancreatic ductal adenocarcinoma.

PET/CT Can Prevent 'Futile Laparotomy' in Resectable/Borderline Pancreatic Cancer

PET/CT Can Prevent 'Futile Laparotomy' in Resectable/Borderline Pancreatic Cancer

PET/CT may prevent unnecessary laparotomy by detecting occult metastatic disease in patients with resectable/borderline pancreatic cancer.

Nab-Paclitaxel Plus Gemcitabine Sustains OS in Metastatic Pancreatic Adenocarcinoma

Nab-Paclitaxel Plus Gemcitabine Sustains OS in Metastatic Pancreatic Adenocarcinoma

Nab-paclitaxel plus gemcitabine sustained overall survival rates compared with gemcitabine alone in patients with metastatic pancreatic adenocarcinoma.

Cetuximab Does Not Improve FOLFOX4 Outcomes for CRC with RAS Mutations

Cetuximab Does Not Improve FOLFOX4 Outcomes for CRC with RAS Mutations

Cetuximab should not be added to first-line FOLFOX4 for patients whose mCRC harbors RAS mutations.

Molecular Subtyping Bests Standard in Predicting Breast Cancer Outcomes

Molecular Subtyping Bests Standard in Predicting Breast Cancer Outcomes

Molecular tumor subtyping offers more accurate prediction of long-term breast cancer outcomes.

Neoadjuvant Veliparib Plus Carboplatin Holds Promise for TNBC

Adaptive randomization study finds neoadjuvant veliparib plus carboplatin may improve pCR in TNBC.

Switching Chemo Regimen After Cycle 1 Not Beneficial in Metastatic Breast Cancer

Switching Chemo Regimen After Cycle 1 Not Beneficial in Metastatic Breast Cancer

Patients with metastatic breast cancer did not benefit from switching to a second-line chemotherapy regimen after one cycle of first-line therapy.

Ramucirumab Does Not Improve Survival in Advanced Breast Cancer

Adding ramucirumab to docetaxel does not improve survival among patients with HER2-negative, advanced breast cancer.

Neoadjuvant Carboplatin, Bevacizumab Improve pCR Rates in TNBC

Adding carboplatin or bevacizumab to standard chemotherapy improves pCR in TNBC.

Novel STAT5 Targets FasL in AML

Experts discuss miR-590, a novel STAT5 oncogenic miRNA that targets FasL in AML.

AE Reporting Sensitivity Relatively Low in Cooperative Group Trials

The current system of AE reporting has modest sensitivity and a demonstrable false positive rate in cooperative group trials.

Telomere Length Associated with Women's Cognition after HCT

Telomere length may be prognostic of cognitive impairment in women after HCT.

ABT-199 Shows Activity in High-Risk Relapsed/Refractory CLL

ABT-199 (GDC-0199) demonstrated antitumor activity in patients with high-risk relapsed/refractory CLL and SLL.

Biomarkers, AlloHSCT Predict Post-AML Relapse Prognosis

Cytogenetic and molecular abnormalities may also be prognostic of post-relapse prognosis.

Sign Up for Free e-newsletters

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs